Abstract:Wen Ting Zhu, 1, &ast Xiang Feng Zeng, 2, &ast Hua Yang, 2 Meng Lei Jia, 1 Wei Zhang, 2 Wei Liu, 2 Sheng Yao Liu 3 1 Department of Pharmacy, Biomedicine Research Center, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, People's Republic of China; 2 Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China; 3 Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Liu, Department of Orthopedics, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, People's Republic of China, Email Sheng Yao Liu, Department of Orthopedics, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, People's Republic of China, Email Background: Osteosarcoma is a malignant bone tumor with a high rate of lung metastasis and mortality. It has been demonstrated that resveratrol can inhibit tumor proliferation and metastasis, but its application is limited due to poor water solubility and low bioavailability. In this study, we proposed to prepare folate-modified liposomes loaded with resveratrol to investigate its anti-osteosarcoma effect in vitro and in vivo. Methods: We prepared and characterized resveratrol liposomes modified with folate (denoted as, FA-Res/Lps). The effects of FA-Res/Lps on human osteosarcoma cell 143B proliferation, apoptosis, and migration were investigated by MTT, cell cloning, wound-healing assay, transwell, and flow cytometry. A xenograft tumor and lung metastasis model of osteosarcoma was constructed to study the therapeutic effects of FA-Res/Lps on the growth and metastasis of osteosarcoma in vivo. Results: The FA-Res/Lps were prepared with a particle size of 118.5 ± 0.71 and a small dispersion coefficient of 0.154 ± 0.005. We found that FA-modified liposomes significantly increased resveratrol uptake by osteosarcoma cells 143B in flow cytometric assay, resulting in FA-Res/Lps, which inhibit tumor proliferation, migration and induce apoptosis more effectively than free Res and Res/Lps. The mechanism of action may be associated with the inhibition of JAK2/STAT3 signaling. In vivo imaging demonstrated that FA-modified DiR-modified liposomes significantly increased the distribution of drugs at the tumor site, leading to significant inhibition of osteosarcoma growth and metastasis by FA-Res/Lps. Furthermore, we found that FA-Res/Lps did not cause any adverse effects on mice body weight, liver, or kidney tissues. Conclusion: Taken together, the anti-osteosarcoma effect of resveratrol is significantly enhanced when it is loaded into FA-modified liposomes. FA-Res/Lps is a promising strategy for the treatment of osteosarcoma. Keywords: resveratrol, liposomes, osteosarcoma, lung metastasis, JAK2/STAT3 pathway Osteosarcoma (OS) is the most common malignant bone tumor. Most cases occur in children and young adults 10 to 30 years of age. Approximately 10 to 15% of patients with newly diagnosed osteosarcoma present with metastatic disease, primarily in the lung. The 5-year survival rate is approximately 60% among patients with localized osteosarcoma but is only 20% among patients presenting with metastases or recurrent disease. 1,2 The mainstay of treatment for OS is surgical resection of the primary tumor, pre-and post-operative chemotherapy has been effective in improving patient survival. Unfortunately, chemotherapeutic drugs are not good for treating OS lung metastases and are susceptible to toxic side effects, such as adriamycin, which has significant cardiac effects, so it is urgent to find a highly effective and less toxic drug for treating OS. 3,4 Nowadays, scientists are investigating the use of various naturally-occurring bioactive compounds against OS. 5,6 Resveratrol (Res), a non-flavonoid polyphenolic organic compound, has antioxidant, anti-inflammatory, 7 anti-cancer, 8 and cardiovascular protection. 9 Furthermore, Res has a significant inhibitory effect on a wide range of tumor cells, including hepatocellular carcinoma, 10 breast cancer, 11 colon cancer, 12 gastric cancer 13 , and leukemia. 14 Res has been demonstrated that it can inhibit the growth and metastasis of OS in vitro through NF-κB inhibition 15 and STAT3 pathway inhibition, 16 -Abstract Truncated-

Resveratrol Loaded by Folate-Modified Liposomes Inhibits Osteosarcoma Growth and Lung Metastasis via Regulating JAK2/STAT3 Pathway

Resveratrol is Cytotoxic and Acts Synergistically with NF-κB Inhibition in Osteosarcoma MG-63 Cells.

Oxyresveratrol induces apoptosis and inhibits cell viability via inhibition of the STAT3 signaling pathway in Saos‑2 cells

In silico studies reveal the anti-osteosarcoma targets and action mechanisms of resveratrol

Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1

Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo

Water Extract of Sporoderm-Broken Spores of Ganoderma Lucidum Induces Osteosarcoma Apoptosis and Restricts Autophagic Flux

T52 Attenuates Oncogenic STAT3 Signaling and Suppresses Osteosarcoma.

Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets

Oxyresveratrol Reduces the Migration of Human Osteosarcoma Cell U2OS Via Attenuating STAT3 Activation

Dual Mechanism of Action of Resveratrol in Notch Signaling Pathway Activation in Osteosarcoma

Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway

Network pharmacology, molecular docking, and molecular dynamics simulations shed light on the mechanism behind Gynostemma pentaphyllum's efficacy against osteosarcoma

Long-Circulating and Targeted Liposomes Co-loading Cisplatin and Mifamurtide: Formulation and Delivery in Osteosarcoma Cells

Fh535 Suppresses The Growth Of Osteosarcoma In Vitro And Vivo Via Downregulation Wnt/Beta-Catenin Signaling Pathway

Reduction-responsive Polypeptide Nanomedicines Significantly Inhibit Progression of Orthotopic Osteosarcoma.

LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.

Supplementary Data from Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma

VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways

Activation of Dynamin-Related Protein 1 and Induction of Mitochondrial Apoptosis by Exosome-Rifampicin Nanoparticles Exerts Anti-Osteosarcoma Effect

Psoralidin inhibits osteosarcoma function by down-regulating ITGB1 expression through FAK and PI3K/Akt signaling pathways